Imifoplatin is under clinical development by Promontory Therapeutics and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase II drugs for Pancreatic Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Imifoplatin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Imifoplatin overview

PT-112 is under development for the treatment of advanced solid tumors including squamous or non-squamous non small cell lung cancer (NSCLC), basal cell carcinoma, pancreatic cancer, ovarian cancer, gallbladder cancer, gastric cancer, cholangiocarcinoma, colorectal cancer, thymoma, thymic carcinoma, neuroendocrine carcinoma, intrahepatic cholangiocarcinoma (IHCC), extrahepatic cholangiocarcinoma (EHCC), metastatic hepatocellular carcinoma, urothelial carcinoma (UC), squamous cell carcinoma of the head and neck (SCCHN), castration-resistant prostate cancer (CRPC), breast cancer, liver cancer or hepatic metastasis and relapsed or refractory multiple myeloma. The drug candidate is administered intravenously. It is a phosphaplatin which is a combination of phosphate and platinum. It cats by targeting EIF2S1.

Promontory Therapeutics overview

Promontory Therapeutics is a clinical-stage pharmaceutical company developing phosphaplatins, a family of novel anti-cancer small molecule agents. Its lead product candidate PT-112, is a pyrophosphate-conjugated platinum therapeutic agent that combines apoptotic and immunogenic properties for preventing lung, breast cancer and hematological malignancies. Promontory Therapeutics works in collaboration with various contract research organizations, pharmaceutical companies and universities to study the mechanism of action of its lead drug candidate. The company markets its products through its network of distributors across the US. Promontory Therapeutics is headquartered in New York City, New York, the US.

For a complete picture of Imifoplatin’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.